Literature DB >> 12565689

A comparison of (13)C NMR measurements of the rates of glutamine synthesis and the tricarboxylic acid cycle during oral and intravenous administration of [1-(13)C]glucose.

Graeme F Mason1, Kitt Falk Petersen, Robin A de Graaf, Tomoyuki Kanamatsu, Taisuke Otsuki, Gerald I Shulman, Douglas L Rothman.   

Abstract

13C-labeled glucose is increasingly used in conjunction with magnetic resonance spectroscopy to measure rates of metabolic pathways in the brain in vivo. Most studies of human subjects have used intravenous infusions to administer the labeled compounds, but the procedure is cumbersome and can be uncomfortable for patients with neurological or psychiatric disorders. It may be possible to improve the practicality of the method by administering the glucose orally instead of intravenously. This report describes the performance and comparison of the oral and intravenous protocols in the same subjects. The conclusion is that oral administration does yield the same result as intravenous administration but with lower precision. That sensitivity of the oral protocol may be improved by several ways that are available today.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12565689     DOI: 10.1016/s1385-299x(02)00217-9

Source DB:  PubMed          Journal:  Brain Res Brain Res Protoc        ISSN: 1385-299X


  36 in total

1.  Regional glucose metabolism and glutamatergic neurotransmission in rat brain in vivo.

Authors:  Robin A de Graaf; Graeme F Mason; Anant B Patel; Douglas L Rothman; Kevin L Behar
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

Review 2.  Stable isotope-resolved metabolomics and applications for drug development.

Authors:  Teresa W-M Fan; Pawel K Lorkiewicz; Katherine Sellers; Hunter N B Moseley; Richard M Higashi; Andrew N Lane
Journal:  Pharmacol Ther       Date:  2011-12-23       Impact factor: 12.310

3.  Effects of γ-Aminobutyric acid transporter 1 inhibition by tiagabine on brain glutamate and γ-Aminobutyric acid metabolism in the anesthetized rat In vivo.

Authors:  Anant B Patel; Robin A de Graaf; Douglas L Rothman; Kevin L Behar
Journal:  J Neurosci Res       Date:  2015-02-06       Impact factor: 4.164

Review 4.  13C MRS studies of neuroenergetics and neurotransmitter cycling in humans.

Authors:  Douglas L Rothman; Henk M De Feyter; Robin A de Graaf; Graeme F Mason; Kevin L Behar
Journal:  NMR Biomed       Date:  2011-08-31       Impact factor: 4.044

5.  Regional metabolite levels and turnover in the awake rat brain under the influence of nicotine.

Authors:  Jie Wang; Lihong Jiang; Yifeng Jiang; Xiaoxian Ma; Golam M I Chowdhury; Graeme F Mason
Journal:  J Neurochem       Date:  2010-03-14       Impact factor: 5.372

6.  Cortical substrate oxidation during hyperketonemia in the fasted anesthetized rat in vivo.

Authors:  Lihong Jiang; Graeme F Mason; Douglas L Rothman; Robin A de Graaf; Kevin L Behar
Journal:  J Cereb Blood Flow Metab       Date:  2011-07-06       Impact factor: 6.200

Review 7.  Applications of NMR spectroscopy to systems biochemistry.

Authors:  Teresa W-M Fan; Andrew N Lane
Journal:  Prog Nucl Magn Reson Spectrosc       Date:  2016-02-06       Impact factor: 9.795

8.  Preclinical models for interrogating drug action in human cancers using Stable Isotope Resolved Metabolomics (SIRM).

Authors:  Andrew N Lane; Richard M Higashi; Teresa W-M Fan
Journal:  Metabolomics       Date:  2016-06-29       Impact factor: 4.290

9.  Measurements of the anaplerotic rate in the human cerebral cortex using 13C magnetic resonance spectroscopy and [1-13C] and [2-13C] glucose.

Authors:  Graeme F Mason; Kitt Falk Petersen; Robin A de Graaf; Gerald I Shulman; Douglas L Rothman
Journal:  J Neurochem       Date:  2006-10-31       Impact factor: 5.372

10.  Determination of the glutamate-glutamine cycling flux using two-compartment dynamic metabolic modeling is sensitive to astroglial dilution.

Authors:  Jun Shen; Douglas L Rothman; Kevin L Behar; Su Xu
Journal:  J Cereb Blood Flow Metab       Date:  2008-09-03       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.